The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2026 | DEL-LIVER: percutaneous hepatic perfusion with melphalan for liver-dominant refractory mCRC
Dirk Arnold, MD, PhD, Asklepios Tumorzentrum Hamburg, Hamburg, Germany, describes the trial design and rationale for the DEL-LIVER trial (NCT06607458) evaluating percutaneous hepatic perfusion (PHP) with melphalan in patients with measurable liver-dominant refractory metastatic colorectal cancer and limited extrahepatic disease. The use of PHP allows delivery of a high dose of melphalan directly into the liver via the blood vessels. The trial will compare standard intravenous systemic therapy alone versus systemic therapy with PHP. This interview took place at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancer 2026 Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
